Table 1.
Baseline patient characteristics.
| Characteristic | ETV (n = 180) | TDF (n = 224) | P |
|---|---|---|---|
| Age, mean ± SD, years | 45.4 ± 10.8 | 44.5 ± 11.4 | 0.51 |
| Male sex, n (%) | 106 (58.9) | 120 (53.6) | 0.31 |
| BMI, kg/m2, median (IQR) | 23.2 (21.2, 25.6) | 23.2 (21.0, 25.5) | 0.49 |
| Cirrhosis, n (%) | 67 (37.2) | 78 (34.8) | 0.68 |
| Diabetes, n (%) | 23 (12.8) | 17 (7.6) | 0.10 |
| Hepatitis e antigen positivity, n (%) | 118 (67.4) | 128 (57.1) | 0.038 |
| HBV DNA, log10(copies/mL), median (IQR) | 7.71 (6.74, 8.64) | 7.44 (6.33, 8.53) | 0.32 |
| Platelet, × 103/μL, median (IQR) | 158 (112, 198) | 155 (115, 200) | 0.93 |
| Albumin, g/dL, median (IQR) | 4.1 (3.7, 4.5) | 4.2 (3.8, 4.5) | 0.68 |
| Bilirubin, mg/dL, median (IQR) | 0.77 (0.54, 1.33) | 0.78 (0.55, 1.07) | 0.36 |
| PT, INR, median (IQR) | 1.06 (1.00, 1.22) | 1.06 (1.00, 1.14) | 0.30 |
| ALT, IU/L, median (IQR) | 83.5 (38.3, 154.0) | 85.0 (42.0, 160.5) | 0.54 |
| Creatinine, mg/dL, median (IQR) | 0.9 (0.8, 1.1) | 0.9 (0.7, 1.0) | 0.013 |
| Child–Pugh score, median (IQR) | 5.0 (5.0, 6.0) | 5.0 (5.0, 5.0) | 0.012 |
| GAG-HCC score, median (IQR) | 85.9 (72.6, 107.8) | 82.7 (65.6, 105.9) | 0.14 |
| CU-HCC score, median (IQR) | 8.5 (7.0, 23.5) | 7.0 (4.0, 20.5) | 0.31 |
| PAGE-B score, median (IQR) | 14.0 (10.0, 16.0) | 12.0 (8.0, 16.0) | 0.40 |
| Treatment response at 1 year, n (%) | |||
| Biochemical | 116 (67.4) | 132 (62.3) | 0.33 |
| Serologicala | 80 (49.7) | 93 (49.5) | > 0.99 |
| Virologicalb | 117 (68.4) | 170 (79.4) | 0.018 |
| Sustained virological suppression, n (%) | 85 (48.0) | 126 (62.4) | 0.005 |
| Duration of follow-up, month, median (IQR) | 64.0 (30.5, 84.3) | 49.1 (37.7, 62.2) | < 0.001 |
ETV entecavir, TDF tenofovir disoproxil fumarate, SD standard deviation, IQR interquartile ranges, BMI body mass index, HBV hepatitis B virus, PT prothrombin time, INR international normalized ratio, ALT alanine aminotransferase, GAG-HCC guide with age, gender, HBV DNA core promoter mutations and cirrhosis, CU Chinese University.
aHepatitis e antigen seroconversion.
bUndetectable HBV DNA by polymerase chain reaction with a detection limit of 10 IU/mL.